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Abstract
Radiation therapy is one of the most frequently used methods for treating
cancer patients.  Therefore improving the quality of the treatment by
using new irradiation technologies is one of the radiotherapist's constant
concerns.  The use of accelerators for delivering protons, heavier
charged particles and secondary beams such as neutrons brings further
improvement in dose distribution and in interesting biological properties
for radiations producing a high Linear Energy Transfer (LET).
Cyclotrons have been present in this field since the early history of
radiotherapy and they could play a major role for future dedicated
hospital-based facilities which include not only an accelerator but also
specific beam-transport and beam-delivery systems.  Modern cyclotron
technology exists today to meet all of the requirements within a
reasonable budget.  Specific performances and several cyclotron designs
are presented.
1 . INTRODUCTION
Heavy particles (protons, light ions, neutrons) offer a unique opportunity for improving
the quality of radiation therapy.  Their use has been pioneered over four decades at Berkeley
where there was a very active collaboration between nuclear physicists, cyclotron designers,
physicians and biologists and this fact is well illustrated by the early history of the cyclotron and
its application in radiotherapy.
Ernest Lawrence, inventor of the cyclotron, started in the late thirties a collaborative work
with his brother John [1], a young physician, Paul Aebersold and Richard Stone [2] on the use
of neutrons in the treatment of cancers.  But there was at this time no basic biological
information available to provide a rationale for the use of neutrons in preference to X-rays.
Therefore an unexpectedly high incidence of late morbidity appeared.  A renewed interest
occurred in the early sixties following a great deal of radiological work carried out by
M. Catterall [3] and D. Bewley in the Hammersmith Hospital in London.  This work explained
the radioresistance of tumours and the role of the LET.  Therefore the specifications required for
neutron therapy are now well known and modern cyclotrons are the standard tool for this
application.
In 1946, Robert Wilson [4] mentioned that the properties of beams of mono-energetic
charged particles such as protons and ions (deposition of a large fraction of their kinetic energy
in a small volume at the end of their range (Bragg peak and distal dose fall off), small lateral
scattering) could lead to a new radiotherapeutic tool.  Again the high energy cyclotrons in
Berkeley [5-6] were used for the first treatment with charged particles.
Table 1 presents a short review of cyclotron-based facilities running a medical programme
(most of them part time).  The figures on patient statistics are from the Newsletter "Particles"
issued in January 1994, which is sponsored by the proton therapy co-operative group (PTCOG)
and edited by Janet Sisterson from the Harvard Cyclotron Laboratory.  The type and the










Harvard, Mass. (USA) 1961 6010 Dec. 1993 Synchrocyclotron 160
LBL 184 inch (USA) (1) 1954 2200 1991 Synchrocyclotron 932-a
Uppsala (Sweden) (2) 1957 107 June 1993 SF-synchrocyclotron 200
Dubna (Russia) 1964 108 Aug. 1992 Synchrocyclotron 680
St Petersbourg (Russia) 1975 719 June 1991 Synchrocyclotron 1000
PSI (Switzerland) 1984 1363 May 1993 Isochronous cyclotron 72
Clatterbridge (UK) (3) 1989 463 Jan. 1994 Isochronous cyclotron 62
Louvain-la-Neuve (B) (3) 1991 21 Nov. 1993 Isochronous cyclotron 85
Nice (France) (3) 1991 370 May 1994 Isochronous cyclotron 65-H-
Orsay (France) (4) 1991 235 May 1993 Synchrocyclotron 200
(1) From 1975 to 1987 the old pioneer 184-inch synchrocyclotron was also used for AVM treatment and
earlier for pituitary irradiations.
(2) The old  185 MeV synchrocyclotron has been converted into a 200 MeV sector-focused synchrocyclotron
(3) These modern lower energy isochronous cyclotrons are also used for neutron therapy.
(4) Old synchrocyclotron improved in 1973.  The maximum energy ( 200 MeV) will be used in the future for
large-field treatment.  It is presently used at lower energies (73 MeV) for eye treatment.
Table 2 presents planned facilities and new designs based on cyclotrons for high energy
proton therapy.  The PSI (Switzerland) facility will be operational in 1994.  Proton therapy is
also scheduled or proposed in several nuclear physics research centres using sophisticated
variable-energy cyclotrons.  The four last lines present new designs for dedicated hospital-based
cyclotrons which are proposed by research centres and European industrial companies (IBA-
Belgium and SIEMENS-Germany).  The characteristics of these designs are presented in the last
section.
Table 2
Planned  facilities  and new designs for proton therapy based on cyclotrons
To date the cyclotrons which were used for medical purposes have been machines originally
built for nuclear physics research.  It is time now for accelerators dedicated to medical use, with
sufficient energy to reach deep-seated tumours.  Modern cyclotrons associated with specific
beam delivery systems could play a key role for the development of hospital-based facilities
aiming at treating a large number of patients.  
2 . PHYSICAL AND BIOLOGICAL RATIONALE
Therapy with heavy particles (protons, light ions, neutrons) is based on two factors:  
Institutions Cyclotron type E max
(MeV)
Remarks
PSI, Villigen (CH) Degraded beam from the 590-MeV
ring cyclotron
250 Dynamic beam spreading
New gantry
Ready in 1994
KVI/AGOR (NL) Superconducting compact 200 Variable energy for
nuclear physics
Uppsala (S) SF synchrocyclotron 200 Gantry project
HMI, Berlin (D) Separated-sector cyclotron ~ 75 Eye treatment
TRITRON, Munich
(D)
First fully superconduting cyclotron
(RF + Magnet)
64 Eye treatment
MSU (USA) Superconducting compact 250 Dedicated







New industrial designs for
dedicated hospital-based
facilities
- improved physical selectivity for charged particles, which means the delivery of a
homogeneous dose to the tumour volume while minimizing the dose to the surrounding
healthy tissues.
- improved biological effectiveness for light ions and neutrons due to the dense ionizing
tracks produced by these particles.
2 . 1 Physical selectivity
Figure 1 presents a comparison (from Dr. H. Blattmann, PSI) of depth-dose distribution
for the various types of radiation used in radiotherapy.  
The advantages of protons are based on two
characteristics:
 - The dose delivered by a proton rises as the
proton slows down, reaching about 4 times the
entrance dose near the stopping point, the '
Bragg peak', and is zero beyond that point.
Protons in a mono-energetic beam have very
nearly the same range (the straggling is weak)
and then deliver the maximum dose at the same
depth which is determined by their kinetic
energy.  
- Protons do not deviate very much from a
straight line so that very sharp collimation is
possible (the multiple scattering is also weak).
A range modulation is necessary to deliver a
uniform dose to tumours whose depth exceeds the
width of the Bragg peak but even a range modulated
proton beam has a very favorable dose profile to treat
deep seated lesions.  
2 . 2 Biological effectiveness
Densely ionizing tracks produced by light ions or by neutrons, when they hit a cell,
produce more concentrated local damage and have a more immediately lethal effect than the
scattered minor lesions inflicted by weakly ionizing particles.  As a result, these high-LET
radiations exhibit differences in their biological properties when compared to low-LET radiation
(photons and protons) which may be summarized as follows:
a) Reduction in the differences in radiosensitivity for different types of cell.
b) Reduction in the differences in radiosensitivity related to the phase of the cell in the mitotic
cycle.
c) Less repair phenomena and, as a consequence, less difference between the responses of
the cell populations to fractionated irradiation.
Therefore all cell populations, in all conditions, tend to respond in a similar way when exposed
to high-LET radiation.  This has important consequences for hypoxic cells, less sensitive to
radiation, and often present at the centre of large, poorly-vasculated tumours.  (Radiochemical
reactions in water are in many cases mediated by free-radical oxygen atoms, so it is not
surprising that the absence of molecular oxygen reduces the sensitivity.)  The effect of oxygen is
less important for high-LET particles.
Fig. 1  Depth-dose distribution for
various types of radiation
It follows that high-LET (light ions and neutrons) treatment is particulary useful for
radioresistant tumours, insensitive to normal X-rays.  These will often be large,
deoxygenated tumours with slowly growing cells.
Figure 2 shows the two quantities
which express these biological effects
relatively to photons: the Oxygen
Enhancement Ratio (OER) and the
Relative Biological Efficiency (RBE)
versus the LET.  For light ions the
increased ionization density  leads not
only to a dose rising with depth, but also
to a change in the radiation quality.
Radiation at higher LET has an increased
RBE up to about 200 keV/mm, beyond
which the RBE falls.  Consequently the
biologically effective dose at a depth,
relative to the entrance region, increases
even more than the physical dose.
3 . MEDICAL REQUIREMENTS FOR A FACILITY
The main requirements could be summarised as follows:
– Accelerator is highly reliable, easy to operate and repair time is low.
– Possibility to use different directions of the beam:  a variable incidence beam (the so-called
rotating gantry) is suitable.
3 . 1 Requirements for heavy charged particles
- Range in tissues:  minimum 3 cm for eye treatment, typically 20 cm, maximum 25 cm
(even more if passive beam spreading devices are used!).  This specification fixes the
energy range.
- Maximum dose rate at the tumour:  5 Gray/minute in a 2 litre volume.  This fixes the
maximum intensity (cf. Table 3)
- Maximum irradiated field:  30 x 30 cm2.
Energies, magnetic rigidity for 20 cm range and intensities (pps) required to deliver a dose
of 5 Gray over a volume of two litres in one minute are listed in Table 3.  From the energy
required it is clear that the proton machines and light-ion machines will be quite different in size
and cost:  the cyclotron is a good competitor with linacs and small synchrotrons for proton
therapy, it is close to the limit for carbon and the synchrotron is the best candidate for neon.
Table 3
Energy, magnetic rigidity for 20 cm range and intensities required to deliver







Fig. 2  Biological effects relative to different photons
p 175 2.00 2.1010
C 330 5.67 109
Ne 470 6.98 5.108
3 . 2 Requirements for neutron therapy
Many aspects need to be considered in order to specify the characteristics of the accelerator
and the most relevant are summarised below:
– Skin protection:  this fixes the position of the build-up >2 cm
– Depth dose distribution:  the 50% isodose should be, at least, at 15 cm depth (see Fig. 3)
– treatment time not exceeding 4 minutes to obtain treatment conditions similar to photons.
Taking into account the geometry of the collimator which defines the distance between the
target and the patient, this condition fixes the intensity of the beam delivered on the target.
Fig. 3  Depth-dose distribution of the MEDICYC neutron beam
A fixed-frequency isochronous cyclotron, giving a fixed energy beam, is able to produce
large intensity.  This quality has made the medium-energy cyclotron the work horse of  neutron
therapy programmes.  A 60-MeV, 30- m A proton beam is considered nowadays to be the
standard beam to meet these requirements (deuterons might also be used, e.g. the
superconducting cyclotron installed in the Harper Hospital in Detroit).
4 . CHARACTERISTICS OF A  CYCLOTRON FOR PROTON THERAPY
The development of radiotherapy with proton beams in the 200-250 MeV range is a
challenge to the accelerator community.  Designing a cost effective accelerator, easily installed in
a hospital and simple to operate is an overriding concern.  A small footprint of the accelerator
and its associated switchyard and gantries is an important factor to reduce the total cost of the
facility.  Therefore cyclotrons are good competitors with synchrotrons and linear accelerators for
reasons of energy, magnets, intensities and operation, and these aspects will be described in the
following sections.
4 . 1 Energy
The choice of a fixed energy makes the design simple.  The magnet can then be optimised
and trimming coils are not necessary.  The accelerator is at a fixed radio frequency and all the
settings of the beam lines are fixed.
4 . 2 Magnet
In order to reduce the dimensions of the cyclotron a high magnetic field should be chosen.
This choice has two important consequences :
– It is impossible to accelerate negatively-charged ions due to electromagnetic stripping.
(The MEDICYC high field compact cyclotron in Nice accelerates H- ions up to 65 MeV,
very close to the limit of stripping losses by the magnetic field.)
– Superconducting magnets are attractive because they are about half the weight of room
temperature magnets.
4 . 3 Intensity
An isochronous cyclotron provides a continuous beam with ample intensity.  This is a key
factor for reliability.  Also the beam intensity is easily controlled.  The beam can be very stable
and this is an important advantage for a dynamic beam-spreading system.  To fully benefit from
these advantages an external injection system makes the cyclotron very flexible.  On the
MEDICYC cyclotron which uses an axial injection at 33 kV for the H- beam, a feedback control
of the extracted beam intensity is installed using a few volts on the bunching cavity.  A beam
stability better than 1% could be easily achieved (cf. Fig. 4).
4 . 4 Operation
No sophisticated controls are needed.  A simple programmable Logic Controller is
sufficient.  The operation requires less complexity and this reduces the manpower costs.
5 . PATIENT TREATMENT USING A CYCLOTRON
The main characteristics of a cyclotron beam are its continuous time structure (apart, of
course, from the RF structure at several tens of MHz) and the good extracted beam emittances
and energy dispersion.  These properties have important consequences for the beam delivery
system and for the equipment, the so-called rotating gantry, which provides entry of the beam
into the patient from any arbitrary direction specified by therapy planning.
 Fig. 4  MEDICYC intensity fine adjustment ( ϕ) and control (V)
5 . 1 The beam delivery system
The acceleration of particles takes only 10 to 20 microseconds.  So the beam can be turned
on and off rapidly by acting on the injection process (the device needed can be extremely
simple if one uses an external injection line).  Furthermore it is possible to set up a dynamic
control of the beam intensity with reference to a fast ionisation chamber in the extracted beam
[7], with the effect that the beam can be stabilised at any required level with a response time of
less than 100 microseconds.  Therefore the beam intensity could be strictly constant to better
than 2% over short and long periods, and it can be set to any desired level from a few percent to
the nominal level.  This process can be fully automatic, a separate safety circuit ensuring that no
misoperation of this servomechanism can lead to an overdose for the patient.  If a failure is
detected the beam can be turned off in less than a few tens of microseconds.
These characteristics have important consequences for the beam delivery systems
associated with a cyclotron.  Any-beam delivery system must accomplish a three-dimensional
scanning of the tumour which requires:
– lateral deflection of the beam,
– variable range,
– variable exposure time to achieve a uniform dose,
– position-sensitive monitors,
– rapid switch-off in case of malfunction.
The lateral deflection of the beam for irradiating large fields can be obtained either by
passive scattering using a contoured scatterer (cf. Fig. 5b) following the methods and results of
B. Gottschalk [8] or  by active methods using a magnetic field to deflect the beam.  Figure 5a
shows the price to pay for that method which leads to increasing the cyclotron energy to
compensate for the range losses in the scatterer.  
 F. Farley [9] has proposed a very simple method which is easy to implement with a
cyclotron and is shown in Fig. 6.  It uses a dynamic beam spreading mode by a deflecting
magnet and requires:
Fig. 5b  Beam spreading with a contoured scatterer
`
Fig. 5a  Performance of beam-spreading methods for illuminating a given field
– An upstream modulator for range scanning at 50 Hz and which will spread the beam to a
Gaussian spot (fixed or variable, it does not matter!).  
– A magnet which scans this spot linearly along a line perpendicular to the axis at a low
frequency (1 Hz typical, so only a low power is needed in the magnet which has a small
gap because the deflection is in one plane only).  
The patient is displaced steadily at 5 mm/sec.  The combination of these two effects creates a
raster scan with uniform intensity.  Of course the usual patient collimator and bolus move with
the patient.  
Fig. 6  Simple dynamic beam spreading by moving the patient
This simple method is not difficult to implement and could be easily extended to spot
scanning and conformal therapy, due to the simplicity of intensity control of the cyclotron which
has the advantage of using a rapid feedback for eliminating fluctuations and for varying the
intensity under computer control of the intensity on the injection line.  At PSI [10] a discrete spot
scanning technique has been developed.  For each position the dose is applied by switching on
and off the beam with a kicker magnet which is located within the gantry.
5 . 2 Rotating gantries
In order to reduce the dose to the surrounding healthy tissue a standard technique
conventionally used in radiotherapy is to treat the tumour several times with beams coming from
different directions.  This device is called a rotating gantry:  the beam comes in along the axis, is
guided away from the centre and bent back towards the axis to cross it orthogonally.  If the beam
line ends at the axis (i.e. the patient is located on the axis) the gantry is said to be isocentric.
This component represents a significant fraction of the total cost of the facility.  The energy of
the beam extracted from the cyclotron is degraded at the exit of the gantry, so the settings of all
the magnets are fixed.  In contrast with a synchrotron where the energy is changed at the
accelerator this whole beam line needs to be reset exactly.  This factor could reduce the costs of
this equipment.
Several types of gantry have been studied in the past years, Fig. 7 shows schematically
their main properties and typical dimensions.
Fig. 7  Various gantry designs
6 . DEDICATED CYCLOTRON DESIGNS
6 . 1 Cyclotrons for neutron therapy
The high intensity required for this radiotherapy is easily achievable from isochronous
cyclotrons.  Figure 8 shows the median-plane view of the 65 MeV room temperature cyclotron
designed and installed in Nice.  Use has been made of H- acceleration to facilitate the extraction
system [11].  A 62-MeV commercial cyclotron designed by Scanditronix is installed in the
Clatterbridge Douglas Centre.  A compact superconducting cyclotron rotating around the patient
has been constructed by H.G. Blosser [12] and is running in the Harper Hospital in Detroit
(USA).  The 40 MeV deuteron maximum energy orbit has a radius of only 30 cm (cf. Fig. 9).
The structure of this cyclotron weighs less than 25 tons and this allows the entire cyclotron to be
mounted directly on a rotating gantry so that neutrons produced in an internal target can be
directed at a supine patient from any direction.
6 . 2 Cyclotrons for proton therapy
For proton therapy at 60–90 MeV, useful for treatments such as the ocular melanoma,
several medium-energy cyclotrons are operating.  This energy domain is close to that of neutron
therapy and therefore several cyclotrons are running both programmes;  Clatterbridge (UK) and
Nice (F) which are fully dedicated machines, Louvain-la-Neuve (B) which is running part time
for medicine, are typical examples.
There is now an increasing number of new projects aimed at treating many tumour types at
any depth and therefore cyclotrons in the 200 MeV range are good candidates.  These machines
could use either a room-temperature magnet or a superconducting magnet.  The characteristics of
four designs are presented below.
6.2.1  A room-temperature design
A commercial design [13] by the Ion Beam Applications company in Belgium has chosen a
high field (2.15 Tesla on the extraction radius) produced by conventional coils (cf. Fig. 10  and
Table 4).  This cyclotron and the associated gantry will be installed in the coming years in the
new proton therapy facility to be built at Massachusetts General Hospital in Boston (USA).
Fig. 8 Median-plane view of the Fig. 9  Median-plane view of the
MEDICYC 65-MeV cyclotron rotating cyclotron in Detroit
Fig. 10  IBA 235-MeV, room-temperature
cyclotron.
Table 4
Characteristics of the IBA 235-MeV cyclotron
Magnet
Number of sectors 4
Yoke external diameter 4.30 m
Current density in the coil 155 A/cm2
Total weight 220 tons
Power 200 kW
R F
Two dees in opposite valleys
Frequency 107.17 MHz
Harmonic mode 4
Dee voltage injection 60 kV
Dee voltage extraction 130 kV




6.2.2  Compact superconducting cyclotron designs
Figure 11 shows a compact superconducting sector-focused cyclotron capable of
producing a continuous beam of 238 MeV protons.  It has three spiral sectors with a
supplementary groove along the centre of each sector, making it more like a six-sector machine
and thus avoiding the well known n r = 3/2 resonance (this technique has been well established at
the AGOR facility in Holland).  Three RF cavities, galvanically connected in the central region,
operate on the third harmonic of the particle frequency.  They provide a large energy gain per
turn in order to complete the acceleration in about 400 turns.  Table 5 gives the main
characteristics of this design which was made by SIEMENS and The Cyclotron Laboratory of
CAL in Nice [14].
Fig. 11  The CAL/SIEMENS 238-MeV, superconducting cyclotron.
Table 5
Main characteristics of the CAL/SIEMENS 238-MeV superconducting cyclotrons
Magnet
Number of sectors 3 i.e. "pseudo 6 sectors"
Yoke external diameter 3.10 m
Current density in superconducting coil 6800 A/cm2
Total weight 80 tons
Power including refrigerator 35 kW
RF
3 dees in galvanically connected
Frequency 110MHz
Harmonic mode 3
Dee voltage injection 80 kV
Dee voltage extraction 130 kV
RF power 120 kW
Miscellaneous
Injection:  Two options axial or radial
(neutral beam + central stripper)
H.G. Blosser from Michigan State University (USA) has designed a 250-MeV four-
sector, compact, superconducting cyclotron for proton therapy [15].  Figure 12 shows a
horizontal section of this machine where magnet hills and dees repeat with 90˚ spacing.  Protons
are produced by an internal ion source.
Fig. 12  The MSU 250-MeV superconducting cyclotron
6.2.3  A superconducting-ring cyclotron design
Figure 13a shows the  layout of a 200-MeV superconducting-ring cyclotron proposed by
the National Accelerator Centre in South Africa [16].  The magnet is made of four 15-ton sectors
with superconducting S-coils located in separate cryostats at the radial boundary of each sector.
A small internal ion source is located in the central region.  The design should, in principle,
allow extraction at different energies by moving radially the extraction elements located in the
low-field valleys.  Figure 13b presents the median-plane distribution of the magnetic field with
isofield contours at 0.3 T intervals from 0.6 to 4.2 T within a radius of 1.2 m.
Fig. 13  The NAC 200-MeV cyclotron.  a) Layout  b) median-plane magnetic field.
6 . 3 Booster cyclotron
Several neutron therapy centres presently using low-energy proton therapy are examing the
potential for boosting the beams for high-energy proton therapy in the 200-MeV range.  With
minor modifications any cyclotron can accelerate negatively-charged ions.  It is easy to extract a
neutral beam using a thin stripper.  This beam will have good optical properties, in particular a
small divergence, allowing it to be transported a long way and traverse the magnetic field of a
compact superconducting accelerator.  This neutral beam is injected by a second stripping foil at
the appropriate radius.  Figure 14 presents a schematic layout of such a booster [17].  An
interesting feature is that all commercial cyclotrons dedicated to the production of radio-isotopes
are accelerating negatively-charged ions and could be used as injectors.
Fig. 14  Boosting an existing cyclotron
7 . CONCLUSIONS
Cyclotrons are good candidates for radiotherapy with heavy particles.
7 . 1 Intensity control:  flexible, fast and safe
As is well known a cyclotron is capable of accelerating large intensities.  Therefore
isochronous cyclotrons are well-suited accelerators for neutron therapy.  Moreover, for proton
therapy the acceleration takes only 10 to 20 microseconds (typical value), so the beam can be
turned on and off rapidly by acting on the low energy end of the machine (external injection line
if any or ion source).  Furthermore a dynamic control of the intensity can be easily realised.  
The system is safe because in the case of a failure or danger condition the beam can be
turned off in less than 20 microseconds by cutting the injected beam.  During this delay the
patient would receive at most one millionth of the standard dose.
7 . 2 Costs saving
A standard proton therapy facility based on a cyclotron (small footprint of the equipment)
reduces the cost of the building.  To this end a superconducting cyclotron in addition to a
compact gantry is attractive.  In addition the running costs are reduced when using a
superconducting coil (total power in the magnet about 30 kW).  
7 . 3 Controls and operation:  easy and cheap
A fixed frequency isochronous cyclotron, giving a fixed energy to the accelerated ions, is a
simple accelerator to operate:  a PC is sufficient to tune and control the cyclotron.
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